Cargando…

Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma

INTRODUCTION: Relapsed histologically aggressive non-Hodgkin’s lymphoma (NHL) has a poor prognosis; relapsed patients who respond to second-line chemotherapy have a better outcome after BMT, while those who do not respond to second line or are unfit for BMT have a worse prognosis and new treatments...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Bary, N, Hashem, T, Metwali, H, Abd el Ghany, A, Magied, HA, El-Herbeiny, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223995/ https://www.ncbi.nlm.nih.gov/pubmed/22276009 http://dx.doi.org/10.3332/ecancer.2009.144

Ejemplares similares

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit
por: Masci, G, et al.
Publicado: (2012)

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic
por: Imaduddin, Mohammed, et al.
Publicado: (2021)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

PB2078: A RETROSPECTIVE ANALYSIS OF THE EFFICACY OF LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE FOR TREATMENT IN PATIENTS WITH LOW GRADE NON-HODGKIN LYMPHOMA
por: Han, B., et al.
Publicado: (2022)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
por: Pannier, Diane, et al.
Publicado: (2018)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
por: Soriano, Jorge L., et al.
Publicado: (2011)

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
por: Shi, Haotian, et al.
Publicado: (2023)

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
por: Lu, Qianyi, et al.
Publicado: (2020)

Effectiveness and toxicity of metronomic oral cyclophosphamide for recurrent or platinum-refractory ovarian cancer: A meta-analysis
por: Huang, Lili, et al.
Publicado: (2022)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
por: Sheng Sow, Heng, et al.
Publicado: (2013)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma
por: Mercurio, Sandy, et al.
Publicado: (2013)

Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis
por: Isozaki, Takeo, et al.
Publicado: (2010)

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
por: Bobillo, Sabela, et al.
Publicado: (2021)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
por: Hájek, R, et al.
Publicado: (2017)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
por: Cebon, J. S., et al.
Publicado: (1990)

Can a rational design for metronomic chemotherapy dosing be devised?
por: Maraveyas, A, et al.
Publicado: (2005)

Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
por: Skavatsou, Eleni, et al.
Publicado: (2021)

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice
por: Malvicini, Mariana, et al.
Publicado: (2012)

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
por: Anwer, Faiz, et al.
Publicado: (2015)

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
por: Cook, Joselle, et al.
Publicado: (2022)

Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
por: Günther, M, et al.
Publicado: (2008)

Metastatic Primary Duodenal Adeno-Carcinoma Responding to Metronomic Oral Cyclophosphamide Chemotherapy
por: Bandyopadhyay, Anis, et al.
Publicado: (2014)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
por: Alagkiozidis, Ioannis, et al.
Publicado: (2015)

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report
por: Peristeri, Dimitra V., et al.
Publicado: (2021)

Long‐term outcomes of combined intravitreal methotrexate and systemic high‐dose methotrexate therapy in vitreoretinal lymphoma
por: Cheng, Chieh‐Lung, et al.
Publicado: (2023)

Weight loss effects of methotrexate and cyclophosphamide
por: Bridges, Dave
Publicado: (2017)

Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tdsiki1bfm3vpvkjbrvui50dss